Patients with immunomodulated inflammatory diseases are not at higher risk for breakthrough COVID-19 infections, apart from those on anti-CD20 therapy, according to findings from several new studies.
This article aims to summarize the latest research on how rituximab affects humoral and cell-mediated response after a COVID-19 vaccine primary series, and whether a booster changes patient response.